NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Bridgetech Holdings back to previous page show list

Bridgetech Holdings

address: aa
contact:
key person: Michael Chermak - Chairman & CEO
25+ years of healthcare industry experience
Extensive experience in building and leading world class teams
Founder and CEO of Healthdemographics – industry leading healthcare market pla

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: YES

SFDA approved: NO

Approvals:
GLP: NO
GMP: NO
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: NO
Active Pharmaceutical: NO
R&D: NO
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 

Bridgetech Holdings International, Inc. is supporting China’s need for Western healthcare by establishing itself as the leader in the transfer of Western medical technology to China. Bridgetech's vision is to gain financial success through promoting the greatest social good and helping every Chinese consumer gain access to the world’s best medical technology.

Bridgetech’s business model uses significant financial leverage while minimizing the traditional risk associated with the biotech industry. Rather than fund the discovery process, Bridgetech offers biotech companies quick access to much needed clinical trial data, regulatory resources and a path to near term revenue. Bridgetech obtains exclusive China distribution rights for later-stage products which have shown promising efficacy. In exchange for these rights, Bridgetech provides clinical trial data, a revenue share on product distribution, and in some cases, a minimal licensing fee.

Bridgetech Chairman & CEO Michael Chermak Speaking during the CUHK Press Conference   Bridgetech CPPCC Meeting in Shanghai.   Bridgetech at International Cooperation Summit for CEOs & Provincial Governors and Mayors.
Bridgetech Chairman & CEO Michael Chermak Speaking during the Bridgetech and CUHK Partnering Press Conference.   Bridgetech Management Team Attending CPPCC Meeting in Shanghai.   Bridgetech at the International Cooperation Summit for Asia-Pacific CEOs & Provincial Governors and Mayors.

Bridgetech’s “basket approach” to building a portfolio of drugs, devices and diagnostic products mitigates the financial risks associated with concentrating investments into one product. Once China distribution rights are obtained, Guangzhou Bridgetech Medical Technologies Development Limited (GBMT), a wholly foreign owned enterprise ("WFOE") established by Bridgetech in China, will process regulatory approval from China’s State Food and Drug Administration (SFDA).

To efficiently manage this process, Bridgetech launched Bridgetech Medical Technologies Research & Development Limited (BMT R&D), a leading CRO (Clinical Research Organization) in partnership with Chinese University of Hong Kong (CUHK). BMT R&D provides the regulatory resources, clinical infrastructure, and intellectual property protection for Bridgetech’s medical products and services.

To execute our strategy, Bridgetech has assembled a seasoned international management team with extensive operations and healthcare experience. Our team enjoys valuable and longstanding relationships with leading healthcare organizations, key members of the U.S. and Chinese governments, and with the regulatory and medical communities.


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.